CRBP News & Events

Corbus Pharmaceuticals announced the last patient has been enrolled and completed the first clinical visit in the company's CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study is on track to be completed in the summer of 2026. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management.

Corbus Pharmaceuticals announced broad alignment with the FDA on the registration path for CRB-701, the company's next-generation, highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma and cervical cancer. Corbus also announced that Dominic Smethurst is stepping down from his role as chief medical officer; his last day with the company will be June 30. The agreed upon second-line registrational study designs for CRB-701 include: HNSCC: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians' choice chemotherapy with potential accelerated approval using objective response rate as the primary endpoint and potential full approval granted on overall survival benefit. Cervical cancer: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians' choice of chemotherapy or Tivdak with potential accelerated approval using ORR as the primary endpoint and potential full approval granted on OS benefit. Continued interactions with the FDA planned to finalize the protocols and statistical analysis plans for the registrational studies.

Corbus Pharmaceuticals files $300M mixed securities shelf